SOURCE: MMRGlobal, Inc.

MMRGlobal, Inc.

May 09, 2011 08:35 ET

MMRGlobal Technology Partner Acquires 13 Million Shares at More Than 30% Above Market

LOS ANGELES, CA--(Marketwire - May 9, 2011) - MMRGlobal, Inc. (OTCBB: MMRF) announced today that Nihilent Technologies, Inc. has acquired 13 million restricted Rule 144 shares of MMRGlobal at a value of more than thirty percent (30%) above market price, based on the Company's Friday, May 6th closing price. The transaction makes Nihilent one of the largest holders in MMRGlobal. As a result of the transaction, Nihilent will have certain filing and reporting obligations.

Nihilent has been MMR's primary development resource and strategic partner for the last four years on the Company's suite of consumer and professional products and services, including the MyMedicalRecords Personal Health Record (www.mymedicalrecords.com), MyESafeDepositBox virtual vault (www.myesafedepositbox.com) and MMRPro electronic document management system for healthcare professionals (www.mmrpro.com). Nihilent is currently the primary developer and architectural resource for MMRPro and works with MyMedicalRecords and Kodak on the integration of the new Kodak Scan Station 550 which is being sold throughout the United States by MMR's direct sales team and through selected Kodak resellers and distributors.

In addition, Nihilent holds certain licensing rights to the Company's products in India, South Africa and certain parts of the Asia Pacific region. India alone represents a population of over 1.2 billion. Robert H. Lorsch, MMRGlobal Chairman and CEO, and Nihilent senior executives met with executives from Chartis International in South Africa last year with regard to Chartis' global initiatives and introduction of the Company's products in India and South Africa.

Headquartered in Pune, India with offices in the United States and South Africa, Nihilent's operations span North America, Europe, Africa, the Middle East and Asia. Clients include Microsoft®, Barclays, Exxon Mobil, Abbot Laboratories, Volkswagen, Mazda, Bajaj Allianz, the South African Revenue Service, South African Development Bank, South African Airways, and others.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature, including future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company's products are not adopted or viewed favorably by the healthcare community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; risks associated with exposure to fluctuations in foreign currency exchange rates; variations in our quarterly operating results; product integration in physician practices and hospitals; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; ability to establish and maintain strategic relationships and alliances; ability to identify and integrate acquisitions; relationships with partners and licensees; competitive product offerings and promotions; changes in government laws and regulations and other business, economic and technology factors; and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company's marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information